We are live on ! Find out more
FCMV

Foresite Capital Management V Portfolio holdings

AUM $271M
1-Year Est. Return 309.87%
This Fund
S&P 500
This Quarter Est. Return
+16.71%
1 Year Est. Return
+309.87%
3 Year Est. Return
+356.88%
5 Year Est. Return
+250.56%
10 Year Est. Return
–
AUM
$407M
AUM Growth
+$85.3M
Cap. Flow
+$128M
Cap. Flow %
31.35%
Top 10 Hldgs %
90.6%
Holding
20
New
3
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$102M
2
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$48.5M
3
CMPX icon
Compass Therapeutics
CMPX
+$14.6M
4
IVVD icon
Invivyd
IVVD
+$12.1M
5
ACET icon
Adicet Bio
ACET
+$7.29M

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$31.7M
2
NRIX icon
Nurix Therapeutics
NRIX
+$13.5M
3
PHICU
Population Health Investment Co., Inc. Unit
PHICU
+$5.6M
4
PHVS icon
Pharvaris
PHVS
+$5.15M
5
ME
23andMe Holding Co
ME
+$2.71M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Financials 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
1
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$154M 37.81%
9,400,515
+8,798,015
+1,460% +$102M
SLGC
2
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$62M 15.23%
5,326,472
– –
THRX
3
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$40.7M 10.01%
+3,212,732
New +$48.5M
QSI icon
4
Quantum-Si Incorporated
QSI
$168M
$18.4M 4.53%
2,342,061
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$730M
$18.3M 4.49%
1,258,243
– –
CGEM icon
6
Cullinan Oncology
CGEM
$1.05B
$17.6M 4.33%
1,143,006
-1,588,404
-58% -$31.7M
HLTH
7
DELISTED
Cue Health Inc. Common Stock
HLTH
$15.7M 3.85%
1,167,782
– –
KNTE
8
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$15.5M 3.81%
875,001
– –
CMPX icon
9
Compass Therapeutics
CMPX
$373M
$13.9M 3.43%
+4,400,000
New +$14.6M
IVVD icon
10
Invivyd
IVVD
$180M
$12.7M 3.11%
1,745,060
+464,420
+36% +$12.1M
ACET icon
11
Adicet Bio
ACET
$72.8M
$11.9M 2.92%
+42,500
New +$7.29M
HIMS icon
12
Hims & Hers Health
HIMS
$6.5B
$11.2M 2.75%
1,706,922
+650,000
+61% +$4.7M
IRON icon
13
Disc Medicine
IRON
$2.83B
$7.09M 1.74%
81,171
– –
RACB
14
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.88M 1.2%
500,000
– –
ME
15
DELISTED
23andMe Holding Co
ME
$2.71M 0.67%
20,346
-14,654
-42% -$2.71M
PHVS icon
16
Pharvaris
PHVS
$2.39B
$491K 0.12%
34,142
-330,000
-91% -$5.15M
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-250,000
Closed -$2.49M
NRIX icon
18
Nurix Therapeutics
NRIX
$2.43B
– –
-451,522
Closed -$13.5M
LHDX
19
DELISTED
Lucira Health, Inc. Common Stock
LHDX
– –
-485,000
Closed -$760K
PHICU
20
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
– –
-960,000
Closed -$5.6M

Similar funds

MAM
Mullooly Asset Management Wall Township, New Jersey $271M AUM 16.93% 1-Year Est. Return
MLM
Mount Lucas Management Newtown, Pennsylvania $271M AUM 25.49% 1-Year Est. Return
PFG
Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return
MCM
Moerus Capital Management New York $271M AUM 58.78% 1-Year Est. Return
RP
Ravenswood Partners Mclean, Virginia $271M AUM
PCM
Punch Card Management Winter Park, Florida $271M AUM 11.49% 1-Year Est. Return
ACH
Axis Capital Holdings Pembroke, Bermuda $270M AUM 16.26% 1-Year Est. Return
S
Siemens Munich, Germany $272M AUM 183.71% 1-Year Est. Return

Foresite Capital Management V's Q4 2021 Portfolio in Review

As of Q4 2021, Foresite Capital Management V held 20 positions worth $407M, up 26% from $322M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Foresite Capital Management V deployed $128M of net new capital in Q4 2021, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Theseus Pharmaceuticals, Inc. Common Stock: 3,212,732 shares worth $40.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $31.7M trimmed.

  • Foresite Capital Management V's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 3,212,732 shares worth $40.7M.
  • Foresite Capital Management V added most to Pardes Biosciences, Inc. Common Stock in Q4 2021, an estimated $102M increase.
  • Foresite Capital Management V's biggest Q4 2021 reduction was Cullinan Oncology, cutting an estimated $31.7M.
  • Foresite Capital Management V fully exited Nurix Therapeutics in Q4 2021, selling an estimated $13.5M.
  • Foresite Capital Management V's ten largest holdings make up 91% of its $407M portfolio in Q4 2021.
  • Foresite Capital Management V opened 3 new positions and closed 4 in Q4 2021.
  • Foresite Capital Management V's portfolio value rose 26% quarter-over-quarter to $407M.

Based on Foresite Capital Management V's 13F filing for Q4 2021, filed 11 Feb 2022.